# Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)

> **NCT07682922** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 1040 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Edaravone dexborneol sublingual tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07682922
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-09-30
- **Target enrollment:** 1040 (ESTIMATED)
- **Last updated:** 2026-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682922, "Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07682922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*